secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emmaus Life Sciences, Inc. (EMMA)
CIK:        0000822370
Form:       8-K
Filed at:   2022-11-15T23:59:59+00:00
Accession:  0001213900-22-072481
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emmaus Q3 net loss narrows to $0.4M; revenue slides YoY; working capital insufficient
--------------------------------------------------------------------------------

- Q3 net revenues $4.9M, up 15% from Q2 but down YoY from $5.8M; nine-month revenues $12.5M vs $17.6M.
- Q3 net loss $0.4M ($0.01/shr) vs $3.2M loss in Q3 2021; operating loss $0.7M vs $31k.
- Cash and equivalents $1.2M vs $2.3M at Dec 31; working capital insufficient for next 12 months without restructuring.
- First Endari sales in UAE (approved May 2022) and early access in GCC countries boosted Q3 revenue.
- Company discussing restructuring or refinancing of indebtedness and other current liabilities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/822370/000121390022072481/0001213900-22-072481-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/822370/000121390022072481/ea168520-8k_emmauslife.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-072481

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer